Ergomed 주식 주식분석 | 주식가격 | 뉴스 | ERGO.L | GB00BN7ZCY67 | A117XM

날짜	Ergomed 매출	Ergomed EBIT	Ergomed 이익
2030e	269.32 백만 undefined	46.07 백만 undefined	0 undefined
2029e	253.92 백만 undefined	44.32 백만 undefined	0 undefined
2028e	238.66 백만 undefined	42.66 백만 undefined	0 undefined
2027e	235.55 백만 undefined	46.14 백만 undefined	37.57 백만 undefined
2026e	220.14 백만 undefined	41.79 백만 undefined	36.76 백만 undefined
2025e	199.37 백만 undefined	36.96 백만 undefined	29.96 백만 undefined
2024e	183.93 백만 undefined	31.97 백만 undefined	27.18 백만 undefined
2023e	165.51 백만 undefined	27.85 백만 undefined	24.01 백만 undefined
2022	145.26 백만 undefined	20.54 백만 undefined	14.98 백만 undefined
2021	118.58 백만 undefined	19.35 백만 undefined	12.67 백만 undefined
2020	86.39 백만 undefined	14.39 백만 undefined	9.68 백만 undefined
2019	68.26 백만 undefined	7.91 백만 undefined	5.57 백만 undefined
2018	54.11 백만 undefined	-1.04 백만 undefined	-8.98 백만 undefined
2017	47.62 백만 undefined	-2.75 백만 undefined	-4.5 백만 undefined
2016	39.23 백만 undefined	1.36 백만 undefined	-70,000 undefined
2015	30.18 백만 undefined	2.38 백만 undefined	1.55 백만 undefined
2014	21.16 백만 undefined	1.36 백만 undefined	578,000 undefined
2013	15.15 백만 undefined	1.78 백만 undefined	1.55 백만 undefined
2012	14.61 백만 undefined	470,000 undefined	390,000 undefined
2011	12.07 백만 undefined	620,000 undefined	540,000 undefined

	매출	EBIT	이익
2011	12.07 백만 GBP	620,000 GBP	540,000 GBP
2012	14.61 백만 GBP	470,000 GBP	390,000 GBP
2013	15.15 백만 GBP	1.78 백만 GBP	1.55 백만 GBP
2014	21.16 백만 GBP	1.36 백만 GBP	578,000 GBP
2015	30.18 백만 GBP	2.38 백만 GBP	1.55 백만 GBP
2016	39.23 백만 GBP	1.36 백만 GBP	-70,000 GBP
2017	47.62 백만 GBP	-2.75 백만 GBP	-4.5 백만 GBP
2018	54.11 백만 GBP	-1.04 백만 GBP	-8.98 백만 GBP
2019	68.26 백만 GBP	7.91 백만 GBP	5.57 백만 GBP
2020	86.39 백만 GBP	14.39 백만 GBP	9.68 백만 GBP
2021	118.58 백만 GBP	19.35 백만 GBP	12.67 백만 GBP
2022	145.26 백만 GBP	20.54 백만 GBP	14.98 백만 GBP
2023e	165.51 백만 GBP	27.85 백만 GBP	24.01 백만 GBP
2024e	183.93 백만 GBP	31.97 백만 GBP	27.18 백만 GBP
2025e	199.37 백만 GBP	36.96 백만 GBP	29.96 백만 GBP
2026e	220.14 백만 GBP	41.79 백만 GBP	36.76 백만 GBP
2027e	235.55 백만 GBP	46.14 백만 GBP	37.57 백만 GBP
2028e	238.66 백만 GBP	42.66 백만 GBP	0 GBP
2029e	253.92 백만 GBP	44.32 백만 GBP	0 GBP
2030e	269.32 백만 GBP	46.07 백만 GBP	0 GBP

2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023e	2024e	2025e	2026e	2027e	2028e	2029e	2030e
12	14	15	21	30	39	47	54	68	86	118	145	165	183	199	220	235	238	253	269
-	16.67	7.14	40.00	42.86	30.00	20.51	14.89	25.93	26.47	37.21	22.88	13.79	10.91	8.74	10.55	6.82	1.28	6.30	6.32
25.00	21.43	33.33	23.81	26.67	28.21	36.17	35.19	42.65	45.35	40.68	40.69	-	-	-	-	-	-	-	-
3	3	5	5	8	11	17	19	29	39	48	59	0	0	0	0	0	0	0	0
0	0	1	1	2	1	-2	-1	7	14	19	20	27	31	36	41	46	42	44	46
-	-	6.67	4.76	6.67	2.56	-4.26	-1.85	10.29	16.28	16.10	13.79	16.36	16.94	18.09	18.64	19.57	17.65	17.39	17.10
0	0	1	0	1	0	-4	-8	5	9	12	14	24	27	29	36	37	0	0	0
-	-	-	-	-	-	-	100.00	-162.50	80.00	33.33	16.67	71.43	12.50	7.41	24.14	2.78	-	-	-
28.75	28.75	20.94	25.07	29.77	35.57	41.09	44.69	48.63	50.5	50.57	51.29	0	0	0	0	0	0	0	0
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022
0	0	1	0	2	0	-4	-10	4	12	14	14
0	0	0	0	0	1	1	2	3	4	5	5
0	0	0	0	0	0	0	0	0	0	0	0
0	0	0	-1	-2	-4	-1	2	0	0	-3	-8
0	0	0	0	0	1	4	7	3	0	2	2
0	0	0	0	0	0	0	0	0	0	0	0
0	0	0	0	0	0	0	0	0	0	3	3
0	0	1	0	0	-2	0	2	11	18	18	14
0	0	0	0	0	-1	-1	-1	0	0	0	-1
0	0	0	-7	0	-5	-3	-3	-2	-12	-4	-26
0	0	0	-6	0	-4	-2	-2	-1	-11	-3	-24
0	0	0	0	0	0	0	0	0	0	0	0
0	0	0	0	0	0	0	0	-1	-2	-2	-2
0	0	0	11	0	9	2	3	1	1	0	0
0	0	0	9	0	8	2	3	0	0	-2	-2
-	-	-	-1.00	-	-	-	-	-	-	-	-
0	0	0	0	0	0	0	0	0	0	0	0
0	0	1	2	0	0	-1	1	9	4	12	-12
-0.41	0.48	1.31	0.39	-0.29	-3.48	-1.4	0.51	10.79	17.07	17.7	12.93
0	0	0	0	0	0	0	0	0	0	0	0

Ergomed 브루토마진	Ergomed 이익 마진	Ergomed EBIT-마진	Ergomed 이익 마진
2030e	40.72 %	17.11 %	0 %
2029e	40.72 %	17.45 %	0 %
2028e	40.72 %	17.88 %	0 %
2027e	40.72 %	19.59 %	15.95 %
2026e	40.72 %	18.98 %	16.7 %
2025e	40.72 %	18.54 %	15.03 %
2024e	40.72 %	17.38 %	14.78 %
2023e	40.72 %	16.83 %	14.51 %
2022	40.72 %	14.14 %	10.31 %
2021	40.78 %	16.32 %	10.69 %
2020	45.9 %	16.65 %	11.21 %
2019	43.26 %	11.59 %	8.16 %
2018	35.58 %	-1.92 %	-16.6 %
2017	36.99 %	-5.77 %	-9.46 %
2016	30.57 %	3.47 %	-0.18 %
2015	27.74 %	7.89 %	5.14 %
2014	27.27 %	6.44 %	2.73 %
2013	33 %	11.75 %	10.23 %
2012	26.9 %	3.22 %	2.67 %
2011	32.81 %	5.14 %	4.47 %

	브루토마진	EBIT-마진	이익 마진
2011	32.81 %	5.14 %	4.47 %
2012	26.9 %	3.22 %	2.67 %
2013	33 %	11.75 %	10.23 %
2014	27.27 %	6.44 %	2.73 %
2015	27.74 %	7.89 %	5.14 %
2016	30.57 %	3.47 %	-0.18 %
2017	36.99 %	-5.77 %	-9.46 %
2018	35.58 %	-1.92 %	-16.6 %
2019	43.26 %	11.59 %	8.16 %
2020	45.9 %	16.65 %	11.21 %
2021	40.78 %	16.32 %	10.69 %
2022	40.72 %	14.14 %	10.31 %
2023e	40.72 %	16.83 %	14.51 %
2024e	40.72 %	17.38 %	14.78 %
2025e	40.72 %	18.54 %	15.03 %
2026e	40.72 %	18.98 %	16.7 %
2027e	40.72 %	19.59 %	15.95 %
2028e	40.72 %	17.88 %	0 %
2029e	40.72 %	17.45 %	0 %
2030e	40.72 %	17.11 %	0 %

날짜	Ergomed 주당 매출	Ergomed EBIT 당 주식	Ergomed 주당 이익
2030e	5.17 undefined	0 undefined	0 undefined
2029e	4.88 undefined	0 undefined	0 undefined
2028e	4.58 undefined	0 undefined	0 undefined
2027e	4.52 undefined	0 undefined	0.72 undefined
2026e	4.23 undefined	0 undefined	0.71 undefined
2025e	3.83 undefined	0 undefined	0.58 undefined
2024e	3.53 undefined	0 undefined	0.52 undefined
2023e	3.18 undefined	0 undefined	0.46 undefined
2022	2.83 undefined	0.4 undefined	0.29 undefined
2021	2.34 undefined	0.38 undefined	0.25 undefined
2020	1.71 undefined	0.28 undefined	0.19 undefined
2019	1.4 undefined	0.16 undefined	0.11 undefined
2018	1.21 undefined	-0.02 undefined	-0.2 undefined
2017	1.16 undefined	-0.07 undefined	-0.11 undefined
2016	1.1 undefined	0.04 undefined	-0 undefined
2015	1.01 undefined	0.08 undefined	0.05 undefined
2014	0.84 undefined	0.05 undefined	0.02 undefined
2013	0.72 undefined	0.09 undefined	0.07 undefined
2012	0.51 undefined	0.02 undefined	0.01 undefined
2011	0.42 undefined	0.02 undefined	0.02 undefined

	주당 매출	EBIT 당 주식	주당 이익
2011	0.42 GBP	0.02 GBP	0.02 GBP
2012	0.51 GBP	0.02 GBP	0.01 GBP
2013	0.72 GBP	0.09 GBP	0.07 GBP
2014	0.84 GBP	0.05 GBP	0.02 GBP
2015	1.01 GBP	0.08 GBP	0.05 GBP
2016	1.1 GBP	0.04 GBP	-0 GBP
2017	1.16 GBP	-0.07 GBP	-0.11 GBP
2018	1.21 GBP	-0.02 GBP	-0.2 GBP
2019	1.4 GBP	0.16 GBP	0.11 GBP
2020	1.71 GBP	0.28 GBP	0.19 GBP
2021	2.34 GBP	0.38 GBP	0.25 GBP
2022	2.83 GBP	0.4 GBP	0.29 GBP
2023e	3.18 GBP	0 GBP	0.46 GBP
2024e	3.53 GBP	0 GBP	0.52 GBP
2025e	3.83 GBP	0 GBP	0.58 GBP
2026e	4.23 GBP	0 GBP	0.71 GBP
2027e	4.52 GBP	0 GBP	0.72 GBP
2028e	4.58 GBP	0 GBP	0 GBP
2029e	4.88 GBP	0 GBP	0 GBP
2030e	5.17 GBP	0 GBP	0 GBP

	주식 수량
2011	28.75 백만 Aktien
2012	28.75 백만 Aktien
2013	20.94 백만 Aktien
2014	25.07 백만 Aktien
2015	29.77 백만 Aktien
2016	35.57 백만 Aktien
2017	41.09 백만 Aktien
2018	44.69 백만 Aktien
2019	48.63 백만 Aktien
2020	50.5 백만 Aktien
2021	50.57 백만 Aktien
2022	51.29 백만 Aktien
2023e	51.29 백만 Aktien
2024e	51.29 백만 Aktien
2025e	51.29 백만 Aktien
2026e	51.29 백만 Aktien
2027e	51.29 백만 Aktien
2028e	51.29 백만 Aktien
2029e	51.29 백만 Aktien
2030e	51.29 백만 Aktien

EPS-예상치	EPS-실제	보고 분기
0.01	0.02 (124.32 %)	2016 Q4
0.05	0.05 (1.32 %)	2015 Q4
0.04	0.05 (35.31 %)	2014 Q4

%-지분	이름	주식	변경
7.38 %	Aberdeen Standard Investments (Edinburgh)	3,842,733	-864,277
7.24 %	Morgan Stanley & Co. International Plc	3,769,309	1,153,798
5.66 %	Sand Grove Capital Management LLP	2,946,217	920,000
4.56 %	BlackRock Investment Management (UK) Ltd.	2,373,840	-192,729
3.57 %	Alpine Associates Management Inc.	1,861,831	994,706
3.36 %	Slater Investments Ltd.	1,752,000	200
3.14 %	Rathbone Investment Management Ltd.	1,635,837	-1,006
3.08 %	Liontrust Investment Partners LLP	1,601,863	-68,694
2.85 %	Octopus Investments Limited	1,482,034	-4,434,354
2.04 %	Amati Global Investors Limited	1,059,951	739,992
2.02 %	abrdn Investments Limited	1,051,904	-268,307
17.53 %	Reljanovic (Miroslav)	9,129,297	0
1.94 %	Samson Rock Capital LLP	1,012,102	165,514
1.84 %	Montanaro Asset Management Limited	956,000	180,000
1.77 %	BNP Paribas Asset Management France SAS	922,190	-300,000
1.75 %	GWM Asset Management, Ltd.	909,573	909,573
1.59 %	Barclays Investment Solutions Limited	825,745	752,453
1.57 %	Syquant Capital S.A.S	818,000	818,000
1.31 %	Aegon Asset Management Ltd	682,356	373,951
1.29 %	Man Group plc	674,204	674,204
1.29 %	Wasatch Global Investors Inc	669,976	256,176
1.14 %	Franklin Templeton Fund Management Limited	592,131	-40,000
1.01 %	Berenberg Bank (Asset Management)	525,217	0
0.91 %	Brooks Macdonald Asset Management Limited	472,435	-262,318
0.83 %	Royal London Asset Management Ltd.	432,500	-127,602
0.79 %	Danske Bank Asset Management	411,658	-556,457
0.70 %	JPMorgan Asset Management U.K. Limited	363,870	-107,402
0.63 %	Royce Investment Partners	327,131	327,131
0.62 %	Deka Investment GmbH	325,000	135,000
0.56 %	Barclays Wealth	292,417	292,417
0.53 %	Swedbank Robur Fonder AB	273,852	-683,821
0.48 %	INVESCO Asset Management Limited	249,258	-444,152
0.47 %	Invesco Advisers, Inc.	246,319	61,891
0.46 %	BlackRock Institutional Trust Company, N.A.	241,925	-409
0.46 %	Martin Currie Investment Management Ltd.	240,000	0
0.43 %	Ibercaja Gestión S.G.I.I.C., S.A.	224,844	224,844
0.37 %	Wellington Management Company, LLP	192,616	0
0.36 %	Didner & Gerge Fonder AB	190,000	5,000
0.31 %	Mandarine Gestion	159,796	-3,204
0.30 %	Dimensional Fund Advisors, L.P.	156,834	-10,924
0.27 %	Premier Asset Management Ltd	141,613	0
0.26 %	FIL Pensions Management	135,000	-80,000
0.24 %	Lupus alpha Asset Management AG	127,160	160
0.24 %	Fondita Rahastoyhtiö Oy	124,500	16,000
0.21 %	Grandeur Peak Global Advisors, LLC	110,311	-432,110
0.21 %	Valu-Trac Investment Management Ltd.	107,522	0
0.18 %	Seven Canyons Advisors, LLC	94,056	-87,044
0.15 %	Bankinter Gestión de Activos, SGIIC S.A.	78,805	-31,328
0.14 %	Standard Life Assurance Limited	71,557	4,787
0.14 %	Janus Henderson Investors	70,885	-263,745
0.12 %	Causeway Capital Management LLC	64,606	-6,770
0.12 %	Santander Asset Management UK Limited	64,003	8,141
0.11 %	Kredietrust Luxembourg S.A.	56,659	0
0.10 %	Parametric Portfolio Associates LLC	54,622	19,605
0.10 %	James (Ronald)	54,321	0
0.10 %	Groupama Asset Management	49,648	0
0.09 %	UBS Asset Management (UK) Ltd.	48,572	0
0.08 %	California State Teachers Retirement System	40,473	4,142
0.08 %	Rathbone Unit Trust Management Limited	40,000	0
0.08 %	Church House Investments Limited	40,000	0
0.07 %	Baillie Gifford & Co.	38,617	-1,495
0.07 %	Nuveen LLC	37,411	0
0.07 %	Dimensional Fund Advisors, Ltd.	36,100	0
0.07 %	Liontrust Portfolio Management Limited	35,561	-8,269
0.07 %	GW&K Investment Management, LLC	34,952	300
0.07 %	UBS Asset Management (Switzerland)	34,252	0
0.07 %	Lazard Asset Management, L.L.C.	33,892	-33,978
0.06 %	Geode Capital Management, L.L.C.	30,504	0
0.06 %	Legal & General Investment Management Ltd.	30,070	0
0.06 %	Ceresio Investors	28,800	0
0.05 %	DWS Investment GmbH	28,388	4,035
0.05 %	Prior&Nilsson Fond och Kapitalförvaltning AB	28,080	0
0.05 %	Barfield (Richard Timothy)	25,000	0
0.04 %	BlackRock Asset Management Canada Limited	22,506	0
0.04 %	Florida State Board of Administration	21,228	-16,043
0.04 %	Barratt & Cooke Limited	20,683	4,905
0.04 %	The Vanguard Group, Inc.	19,855	2,938
0.04 %	Credit Suisse Funds AG	19,064	0
0.03 %	Margetts Fund Management Limited	17,297	2,556
0.03 %	American Century Investment Management, Inc.	15,984	280
0.03 %	State Street Global Advisors (US)	14,296	0
0.02 %	Nykredit Bank AS	12,199	0
0.02 %	J. M. Finn & Co.	9,800	9,800
0.02 %	Northern Trust Global Investments Limited	9,156	0
0.02 %	Calamos Advisors LLC	8,855	0
0.02 %	Victory Capital Management Inc.	8,545	0
0.02 %	State Street Global Advisors Ireland Limited	8,075	0
0.02 %	Profibrix B.V.	8,055	0
0.02 %	Middleton (Sarah Anne)	7,891	0
0.01 %	KLP Fondsforvaltning AS	6,334	0
0.01 %	Zürcher Kantonalbank (Asset Management)	6,238	0
0.01 %	Vanguard Investments Australia Ltd.	5,834	-1
0.01 %	Mercer Global Investments Management Ltd	5,749	0
0.01 %	Amundi Asset Management, SAS	2,767	0
0.00 %	Pictet Asset Management Ltd.	2,162	0
0.00 %	Evelyn Partners Investment Management LLP	438	438
0.00 %	Scottish Widows Unit Trust Managers Ltd	434	14
0.00 %	BMO Asset Management Inc.	109	0
0 %	The University of Leicester	0	-149,662
0 %	Goodall (Alison)	0	-40,123

이름	관계	이주간 상관관계	원월 상관관계	삼개월 상관계수	여섯달 상관관계	일년간 상관관계	이년 상관관계
Asarina Pharma	공급업체고객	0,56	0,05	0,43	0,61	0,03	-0,58
CEL-SCI	공급업체고객	0,53	0,45	0,18	0,50	0,43	-0,11
JPMorgan Chase	공급업체고객	0,48	0,22	0,49	0,48	0,59	0,89
Jupiter Fund Management	공급업체고객	0,38	0,79	0,86	0,66	0,41	0,28
Abrdn	공급업체고객	0,37	0,41	0,76	0,41	0,31	0,05
BlackRock	공급업체고객	0,31	0,54	0,69	0,66	0,64	0,85

What values and corporate philosophy does Ergomed represent?

Ergomed PLC represents values of innovation, excellence, and integrity. The company is committed to providing high-quality drug development and healthcare services globally. Ergomed's corporate philosophy emphasizes patient-centricity and collaboration with partners to deliver innovative solutions for the pharmaceutical industry. With a focus on scientific expertise and regulatory compliance, Ergomed strives to accelerate the development of new therapies while maintaining the highest ethical standards. As a premier global provider of clinical research and pharmacovigilance services, Ergomed PLC continuously aims to drive improvements in patient outcomes and contribute to the advancement of medical knowledge.

In which countries and regions is Ergomed primarily present?

Ergomed PLC is primarily present in various countries and regions worldwide. The company operates across Europe, including in the United Kingdom, Germany, France, Spain, Italy, and Poland, among others. Additionally, Ergomed has a strong presence in the United States, where it conducts its business operations. This multinational pharmaceutical services company has established its footprint in numerous global markets, enabling it to provide a wide range of services to clients across different geographies.

What significant milestones has the company Ergomed achieved?

Ergomed PLC has achieved several significant milestones. Firstly, the company successfully completed numerous clinical trials, contributing to the advancement of medical research. Additionally, Ergomed PLC expanded its global presence by establishing strategic partnerships and acquiring other companies in the pharmaceutical sector. The company also achieved financial growth, consistently generating positive revenues and increasing shareholder value. Furthermore, Ergomed PLC received various industry recognitions and awards, reflecting its commitment to excellence in drug development services. These notable milestones highlight Ergomed PLC's leadership and strong market presence in the healthcare industry.

What is the history and background of the company Ergomed?

Ergomed PLC is a renowned pharmaceutical services and drug development company. Established in 1997, Ergomed has grown into a global leader in providing specialized solutions to the healthcare industry. With expertise in clinical research, pharmacovigilance, and medical affairs, Ergomed assists pharmaceutical companies in advancing their products through every stage of development. The company's client-focused approach and strategic collaborations have enabled them to successfully support numerous cutting-edge drug development programs. Emphasizing patient safety and regulatory compliance, Ergomed PLC continues to deliver exceptional clinical services to enhance the progress of innovative medical treatments worldwide.

Who are the main competitors of Ergomed in the market?

The main competitors of Ergomed PLC in the market are other companies operating in the Contract Research Organization (CRO) industry, such as IQVIA Holdings Inc., ICON plc, and PRA Health Sciences Inc. These companies provide similar services in clinical trial management, pharmacovigilance, and regulatory affairs. However, Ergomed PLC distinguishes itself by offering specialized expertise in orphan drug development and rare diseases. Its unique position in the market allows Ergomed PLC to cater specifically to the needs of pharmaceutical and biotechnology companies working in these niche areas.

In which industries is Ergomed primarily active?

Ergomed PLC is primarily active in the pharmaceutical and biotechnology industries.

What is the business model of Ergomed?

The business model of Ergomed PLC revolves around providing specialized services to the pharmaceutical industry. As a global company, Ergomed offers a range of solutions including clinical research, pharmacovigilance, and post-approval safety services. By utilizing their expertise and innovative technologies, Ergomed assists pharmaceutical companies in developing and commercializing new drugs safely and efficiently. With a focus on rare diseases and oncology, Ergomed collaborates with partners to design and conduct clinical trials, manage data, analyze results, and ensure compliance with regulatory requirements. Through their comprehensive services, Ergomed PLC contributes to advancing healthcare and improving patient outcomes.

Ergomed 2024의 P/E 비율은 얼마입니까?

Ergomed의 P/E 비율은 25.4입니다.

Ergomed 2024의 KUV는 얼마입니까?

Ergomed의 P/S 비율은 3.75입니다.

Ergomed의 AlleAktien 품질 점수는 얼마인가요?

Ergomed에 대한 AlleAktien 품질 점수는 8/10입니다.

Ergomed 2024의 매출은 얼마인가요?

예상되는 Ergomed 매출은 183.93 백만 GBP입니다.

Ergomed 2024의 이익은 얼마인가요?

예상되는 Ergomed 이익은 27.18 백만 GBP입니다.

Ergomed은 무엇을 하나요?

Ergomed PLC is a global company that specializes in providing clinical services and pharmacovigilance. The company has a diversified portfolio of services and products, which are divided into various divisions. The first division of Ergomed is its core business, the clinical services. Here, the company offers its customers a wide range of services, including budget planning, study design, data management, monitoring, and biometrics. Additionally, Ergomed also provides support to its customers in the submission of applications and regulatory matters. Another division of Ergomed is its pharmacovigilance department. Here, the company offers its customers consultation and support in compliance with pharmacovigilance requirements, monitoring of safety data, and fulfillment of reporting obligations. Furthermore, Ergomed has its own clinical research organization called PrimeVigilance. This offers clinical monitoring, drug risk and safety monitoring, medical review, and training. An important division of Ergomed is its contract research organization (CRO). Here, the company offers its customers support in conducting clinical studies. This includes the design of study protocols, conducting studies, data management and compliance, as well as support in the submission of applications. Ergomed is also involved in drug manufacturing. The company operates its own GMP-compliant manufacturing facility in Amersham, United Kingdom. Here, Ergomed produces drugs for clinical trials as well as on-demand for customers. Another focus of Ergomed is the development of medical devices. The company is working on developing innovative medical devices that enable better patient care and treatment. Overall, Ergomed PLC offers its customers a wide range of services and products, making it an important partner for the pharmaceutical industry. The company specializes in key services that enable its customers to successfully conduct clinical trials and bring drugs safely to the market. Ergomed has extensive industry experience and is committed to always providing innovative solutions to its customers.

Ergomed 배당금은 얼마입니까?

Ergomed은(는) 연간 번의 배당을 통해 0 GBP의 배당금을 지급합니다.

Ergomed이 얼마나 자주 배당을 지급하나요?

Ergomed의 현재 배당금은 계산할 수 없거나, 회사가 배당금을 지급하지 않습니다.

Ergomed ISIN이 무엇입니까?

Ergomed의 ISIN은 GB00BN7ZCY67입니다.

Ergomed WKN은 무엇인가요?

Ergomed의 WKN은 A117XM입니다.

Ergomed 티커는 무엇인가요?

Ergomed의 티커는 ERGO.L입니다.

Ergomed이 얼마만큼의 배당금을 지급합니까?

지난 12개월 동안 Ergomed은(는) 의 배당금을 지급했습니다. 이는 약 의 배당 수익률에 해당합니다. 향후 12개월 동안 Ergomed은(는) 0 GBP의 배당금을 지급할 것으로 예상됩니다.

Ergomed의 배당 수익률은 얼마입니까?

Ergomed의 현재 배당 수익률은 입니다.

Ergomed의 배당금은 언제 지급되나요?

Ergomed은 분기별로 배당금을 지급합니다. 이는 월에 배당됩니다.

Ergomed의 배당금은 얼마나 안전한가요?

Ergomed은(는) 지난 0년 동안 매년 배당금을 지급했습니다.

Ergomed의 배당금은 얼마입니까?

향후 12개월 동안 0 GBP의 배당금이 예상됩니다. 이는 배당수익률 0 %에 해당합니다.

Ergomed이(가) 속해 있는 섹터는 어디인가요?

Ergomed은 '건강' 섹터에 속합니다.

Wann musste ich die Aktien von Ergomed kaufen, um die vorherige Dividende zu erhalten?

Ergomed의 마지막 배당금을 0 GBP만큼 받기 위해선 의 Ex-Tag 전에 주식을 보유하고 있어야 했습니다.

Ergomed의 마지막 배당금 지급일은 언제였습니까?

마지막 배당금 지급일은 입니다.

Ergomed의 2023년도 배당금은 얼마였습니까?

2023년에 Ergomed는 0 GBP를 배당금으로 지급했습니다.

Ergomed는 어떤 화폐로 배당금을 지급하나요?

Ergomed의 배당금은 GBP에 지급됩니다.

Scope 1 - 직접 방출	0.73
스코프 2 - 구매한 에너지로부터의 간접적인 배출	14.29
Scope 3 - 가치 창출 체인 내의 간접 배출	27.02
총 CO₂ 배출량	15.02
CO₂ 감소 전략	✅
석탄 에너지	❌
원자력	❌
동물 실험	❌
펠츠 & 레더	—
살충제	—
팜 오일	—
담배	❌
유전자 변형 생물체	❌
기후 개념	—
지속 가능한 임업	—
재활용 규정	❌
환경 친화적인 포장	❌
위험물질	❌
연료 소비량과 효율성	❌
물 사용량 및 효율성	❌

여성 직원 비율	—
관리 직위에서의 여성 비율	—
아시아 직원 비율	—
아시아 경영진 비율	—
히스패닉/라티노 직원 비율	—
히스패닉/라티노 관리 부문 지분	—
흑인 직원 비율	—
블랙 매니지먼트 지분	—
흰색 종업원의 비율	—
화이트 매니지먼트 지분	—
성인 콘텐츠	❌
알코올	❌
무기	—
총기	❌
도박	❌
군사 계약	❌
인권 개념	✅
개인정보 보호 정책	—
작업 및 건강 보호	✅
카톨릭	✅

환경 보고	✅
이해관계자 참여	✅
콜백 정책	❌
카르텔법	❌

증권거래소	Ergomed 티커
뒤셀도르프	2EM.DU
프랑크푸르트	2EM.F
LONDON	ERGO.L
LONDON STOCK EXCHANGE	ERGO.L
뮌헨	2EM.MU
XETRA	2EM.DE

Ergomed 티커	Ergomed FIGI
ERGOGBX:XS	BBG006T4VX81
2EM:GY	BBG009W8FKZ8

한 눈에 저평가된 주식을 인식하세요

Ergomed 주식 주식과 주식 분석 Ergomed ariva, Ergomed onvista, Ergomed finanzen.net, Ergomed aktienfinder, Ergomed marketscreener, Ergomed marketwatch, Ergomed bloomberg, Ergomed handelsblatt, Ergomed wiwo, Ergomed forum

가격

가격

티커ERGO.L

ISINGB00BN7ZCY67

WKNA117XM

Ergomed 주식 매출, EBIT, 이익 GB00BN7ZCY67 · A117XM

매출, 이익 & EBIT

매출, EBIT, 소득 이해하기

연간 분석 및 비교

투자 기대치 활용

투자 통찰력

Ergomed 매출, 이익 및 EBIT 역사

Ergomed 주식 지표

손익계산서

매출 성장

총 이익률

EBIT와 EBIT 마진

수입과 성장

발행 주식

연간 비교의 해석

기대치와 예측

재무 상태표

재무 상태표 이해

자산

부채

자본

년대비 분석

데이터 해석

Ergomed 주식 마진 GB00BN7ZCY67 · A117XM

마진

매출 총이익률 이해

EBIT 마진 분석

매출 마진에 대한 인사이트

기대치 해석

비교 분석

Ergomed 마진 역사

Ergomed 주식 매출, EBIT, 주당 순이익 GB00BN7ZCY67 · A117XM

매출, EBIT 및 주당 이익

주당 매출

주당 EBIT

주당 수익

예상 값

Ergomed 매출, 이익 및 EBIT 주당 역사

Ergomed 주식 및 주식 분석

Ergomed 역사적인 P/E, EBIT 및 P/S에 따른 평가

Ergomed 주식 수량 GB00BN7ZCY67 · A117XM

매출, EBIT 및 주당 이익

주당 매출

주당 EBIT

주당 수익

예상 값

Ergomed 수익 예상

Ergomed 수익 놀라움

Eulerpool ESG Scorecard© Ergomed 주식을 위해

Eulerpool World ESG Rating (EESG©)

61/ 100

🌱 Environment

👫 Social

🏛️ Governance

환경

소셜 (사회적)

지배구조 (기업 경영)

Ergomed 주식 주주 구조

Ergomed 임원진 및 경영진

Ergomed 공급망

Ergomed 주식에 대한 자주 묻는 질문